![conference banner](/images/conference-banner.jpeg)
Abstract
In this clinical study, a fast chromatographic (HPLC) method has been established for the quantification of β-estradiol. β-estradiol and the IS (verapamil) were separated from plasma using the deproteinisation procedure, followed by injection of the clear solution of the supernatant into the chromatographic system. For the first time, the proposed method employed a monolithic column in the analysis. The analyte was eluted on a monolithic stationary phase column with a carrier composition of phosphate buffer: acetonitrile (pH 3.5) (90: 10, v/v) at a flow rate of 2.0 mL / min. The target drugs were detected at 280 and 310 nm for fluorescence signal. The proposed method showed a calibration graph over 5 - 1000 ng/ mL, with a low concentration of 1.5 ng/mL. The approach was statistically agreed as regards linearity, accuracy, precision, selectivity and stability according to the FDA criteria. The precision of the method as the intraand inter-day study variation did not exceed 3.0 % from the nominal concentration. The accuracy of β-estradiol was observed to be within ±12% of the theoretical value. The method was good applied to mice plasma.
Keywords: β-estradiol, HPLC, monolithic silica column, method of validation, mice plasma, pharmacokinetic study.
Current Pharmaceutical Analysis
Title:Fast Determination of β-estradiol by Chromatographic Method and its Application to Clinical Pharmacokinetics Studies
Volume: 12 Issue: 1
Author(s): Mohammed Hefnawy, Moustafa Mohamed, Amer Alanazi, Sabry Attia and Gamal Abdel-Hafiz Mostafa
Affiliation:
Keywords: β-estradiol, HPLC, monolithic silica column, method of validation, mice plasma, pharmacokinetic study.
Abstract: In this clinical study, a fast chromatographic (HPLC) method has been established for the quantification of β-estradiol. β-estradiol and the IS (verapamil) were separated from plasma using the deproteinisation procedure, followed by injection of the clear solution of the supernatant into the chromatographic system. For the first time, the proposed method employed a monolithic column in the analysis. The analyte was eluted on a monolithic stationary phase column with a carrier composition of phosphate buffer: acetonitrile (pH 3.5) (90: 10, v/v) at a flow rate of 2.0 mL / min. The target drugs were detected at 280 and 310 nm for fluorescence signal. The proposed method showed a calibration graph over 5 - 1000 ng/ mL, with a low concentration of 1.5 ng/mL. The approach was statistically agreed as regards linearity, accuracy, precision, selectivity and stability according to the FDA criteria. The precision of the method as the intraand inter-day study variation did not exceed 3.0 % from the nominal concentration. The accuracy of β-estradiol was observed to be within ±12% of the theoretical value. The method was good applied to mice plasma.
Export Options
About this article
Cite this article as:
Hefnawy Mohammed, Mohamed Moustafa, Alanazi Amer, Attia Sabry and Mostafa Gamal Abdel-Hafiz, Fast Determination of β-estradiol by Chromatographic Method and its Application to Clinical Pharmacokinetics Studies, Current Pharmaceutical Analysis 2016; 12 (1) . https://dx.doi.org/10.2174/1573412911666150216223109
DOI https://dx.doi.org/10.2174/1573412911666150216223109 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Different 6-Aryl-Fulvenes Exert Anti-proliferative effects on Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry The Role of Bile Acids in Pancreatic Cancer
Current Cancer Drug Targets The Involvement of Heat Shock Proteins and Related Molecules in the Resistance to Therapies in Breast and Gynecologic Cancer
Current Cancer Therapy Reviews Prothymosin α and its C-Terminal Immunoreactive Decapeptide Show No Evidence of Acute Toxicity: A Preliminary <i>In Silico</i>, <i>In Vitro</i> and <i>In Vivo</i> Investigation
Current Medicinal Chemistry Targeting the LKB1 Tumor Suppressor
Current Drug Targets Interaction Between Estrogen Receptor Alpha and Insulin/IGF Signaling in Breast Cancer
Current Cancer Drug Targets Tumor-related Molecular Regulatory Mechanisms of Long Non-coding RNA RMST: Recent Evidence
Mini-Reviews in Medicinal Chemistry T-Box Transcription Factor 2 Enhances Chemoresistance of Endometrial Cancer by Mediating NRF2 Expression
Current Protein & Peptide Science Targeting the Ubiquitin-Proteasome Pathway: An Emerging Concept in Cancer Therapy
Current Topics in Medicinal Chemistry Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme
Current Medicinal Chemistry From Natural Products to Designer Drugs: Development and Molecular Mechanisms Action of Novel Anti-Microtubule Breast Cancer Therapeutics
Current Topics in Medicinal Chemistry Tetrandrine for Targeting Therapy Resistance in Cancer
Current Topics in Medicinal Chemistry Involvement of Nucleotide Excision and Mismatch Repair Mechanisms in Double Strand Break Repair
Current Genomics Molecular Docking and 3D-QSAR Studies on Quinolone-based HDAC Inhibitors
Letters in Drug Design & Discovery Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer
Current Drug Targets Scientific Papers and Patents on Substances with Unproven Effects. Part 2
Recent Patents on Drug Delivery & Formulation Estrogen Receptors: Molecular Interactions, Virtual Screening and Future Prospects
Current Topics in Medicinal Chemistry Polyketide Natural Products, Acetogenins from Graviola (Annona muricata L), its Biochemical, Cytotoxic Activity and Various Analyses Through Computational and Bio-Programming Methods
Current Pharmaceutical Design Light Deficiency Confers Breast Cancer Risk by Endocrine Disorders
Recent Patents on Anti-Cancer Drug Discovery The Bax Inhibitor-1 (BI-1) Family in Apoptosis and Tumorigenesis
Current Molecular Medicine